Trastuzumab biosimilar (Shanghai Institute Of Biological)

曲妥珠单抗生物类似药（上海生物制品）

Report date: 2026/04/01 10:41:50

Base Information

Drug NameTrastuzumab biosimilar (Shanghai Institute Of Biological)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShanghai Institute of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A